

1     **Highly functional virus-specific cellular immune response in asymptomatic**  
2                                   **SARS-CoV-2 infection**

3     Nina Le Bert<sup>1</sup>, Hannah E Clapham<sup>2</sup>, Anthony T Tan<sup>1</sup>, Wan Ni Chia<sup>1</sup>, Christine YL Tham<sup>1</sup>, Jane  
4     M Lim<sup>2</sup>, Kamini Kunasegaran<sup>1</sup>, Linda Tan<sup>2</sup>, Charles-Antoine Dutertre<sup>3</sup>, Nivedita Shankar<sup>2</sup>, Joey  
5     ME Lim<sup>1</sup>, Louisa Jin Sun<sup>4</sup>, Marina Zahari<sup>2</sup>, Zaw Myo Tun<sup>2</sup>, Vishakha Kumar<sup>2</sup>, Beng Lee Lim<sup>1</sup>,  
6     Siew Hoon Lim<sup>5</sup>, Adeline Chia<sup>1</sup>, Yee-Joo Tan<sup>6,7</sup>, Paul Anantharajah Tambyah<sup>8</sup>, Shirin  
7     Kalimuddin<sup>1,9</sup>, David Lye<sup>10</sup>, Jenny GH Low<sup>1,9</sup>, Lin-Fa Wang<sup>1</sup>, Wei Yee Wan<sup>5</sup>, Li Yang Hsu<sup>2</sup>,  
8     Antonio Bertoletti<sup>1,11,\*†</sup>, Clarence C Tam<sup>2,12,†</sup>

9  
10    <sup>1</sup>Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore

11    <sup>2</sup>Saw Swee Hock School of Public Health, National University of Singapore and National  
12    University Health System, Singapore

13    <sup>3</sup>Inserm U1015, Gustave Roussy, Villejuif, France

14    <sup>4</sup>Infectious Diseases, Alexandra Hospital, National University Health System

15    <sup>5</sup>Department of Microbiology, Singapore General Hospital, Singapore

16    <sup>6</sup>Infectious Diseases Translational Programme, Department of Microbiology and Immunology,  
17    Yong Loo Lin School of Medicine, National University of Singapore, Singapore

18    <sup>7</sup>Institute of Molecular and Cell Biology, A\*STAR, Singapore

19    <sup>8</sup>Infectious Disease, Department of Medicine, National University Hospital, Singapore

20    <sup>9</sup>Department of Infectious Diseases, Singapore General Hospital, Singapore

21    <sup>10</sup>National Center of Infectious Diseases, Singapore

22    <sup>11</sup>Singapore Immunology Network, A\*STAR, Singapore

23    <sup>12</sup>London School of Hygiene & Tropical Medicine, London, United Kingdom

24    \*Corresponding author: [antonio@duke-nus.edu.sg](mailto:antonio@duke-nus.edu.sg)

25    †These authors contributed equally

1 **One Sentence Summary:** Virus-specific T cells secrete high levels of IFN- $\gamma$  and IL-2 in  
2 asymptomatic SARS-CoV-2 infection.

3 **Abstract:** The efficacy of virus-specific T cells in clearing pathogens involves a fine balance  
4 between their antiviral and inflammatory features. SARS-CoV-2-specific T cells in individuals  
5 who clear SARS-CoV-2 infection without symptoms or disease could reveal non-pathological yet  
6 protective characteristics. We therefore compared the quantity and function of SARS-CoV-2-  
7 specific T cells in a cohort of asymptomatic individuals (n=85) with that of symptomatic COVID-  
8 19 patients (n=76), at different time points after antibody seroconversion. We quantified T cells  
9 reactive to structural proteins (M, NP and Spike) using ELISpot assays, and measured the  
10 magnitude of cytokine secretion (IL-2, IFN- $\gamma$ , IL-4, IL-6, IL-1 $\beta$ , TNF- $\alpha$  and IL-10) in whole blood  
11 following T cell activation with SARS-CoV-2 peptide pools as a functional readout. Frequencies  
12 of T cells specific for the different SARS-CoV-2 proteins in the early phases of recovery were  
13 similar between asymptomatic and symptomatic individuals. However, we detected an increased  
14 IFN- $\gamma$  and IL-2 production in asymptomatic compared to symptomatic individuals after activation  
15 of SARS-CoV-2-specific T cells in blood. This was associated with a proportional secretion of IL-  
16 10 and pro-inflammatory cytokines (IL-6, TNF- $\alpha$  and IL-1 $\beta$ ) only in asymptomatic infection, while  
17 a disproportionate secretion of inflammatory cytokines was triggered by SARS-CoV-2-specific T  
18 cell activation in symptomatic individuals. Thus, asymptomatic SARS-CoV-2 infected individuals  
19 are not characterized by a weak antiviral immunity; on the contrary, they mount a robust and highly  
20 functional virus-specific cellular immune response. Their ability to induce a proportionate  
21 production of IL-10 might help to reduce inflammatory events during viral clearance.

22

23

## 1 **Introduction**

2 Characterization of adaptive immunity mounted against SARS-CoV-2 is crucial for understanding  
3 its role in protection or pathogenesis. Antibodies and T cells act together to reduce the spread of  
4 virus within the host and to eradicate the pathogen from infected cells. However, the protective  
5 immune response can also trigger pathological processes characterized by localized or systemic  
6 inflammatory events. Inflammation and tissue damage can result from the direct lysis of infected  
7 cells by virus-specific antibodies and T cells, or from the release of inflammatory mediators  
8 produced by the infected cells and activated myeloid cells. These scenarios have been reported in  
9 the pathogenesis of COVID-19 (1). In more severe cases, systemic high levels of inflammatory  
10 cytokines (IL-1 $\beta$ , IL-6), presence of activated monocytes in the circulatory compartment (2, 3) and  
11 in the lung (4) co-exist with virus-specific antibodies and T cells (5). Thus, the question of whether  
12 virus-specific antibodies or T cells are preferentially mediating protection or damage remains open.  
13 Antibodies against SARS-CoV-2 Spike (S) protein have protective ability in vitro, but their titers  
14 in COVID-19 patients have been reported to be positively correlated with disease severity (6, 7).  
15 Similarly, a direct relation with disease severity has been reported in studies of SARS-CoV-2-  
16 specific T cell frequencies in COVID-19 patients. A broader and quantitatively more robust SARS-  
17 CoV-2-specific T cell response has been demonstrated in convalescent cases of severe COVID-19  
18 in comparison to mild cases (8). However, the positive relation between SARS-CoV-2-specific T  
19 cell quantity and disease severity was not confirmed in recent studies measuring SARS-CoV-2-  
20 specific T cells in the early phases of COVID-19. Early induction and more robust SARS-CoV-2-  
21 specific CD4 and CD8 T cell response has been associated with milder disease development (9,  
22 10). In addition, a protective role of T cells has been demonstrated in animal models of Coronavirus  
23 infections, in which virus-specific T cells clear the virus with limited lung pathology (11, 12).

1 In this work we expand our investigation into virus-specific T cells in SARS-CoV-2 infection by  
2 studying asymptomatic SARS-CoV-2 infected individuals. They constitute a large proportion of  
3 infected individuals (13) and should hold the key to understanding the immune response capable  
4 of controlling the virus without triggering pathological processes. However, current knowledge of  
5 their antiviral immunity is limited. SARS-CoV-2-specific antibodies (14) and T cells are induced  
6 in asymptomatic individuals (15), but the reported lower magnitude of antibodies (14) and T cell  
7 responses (15, 16) has been interpreted as a sign that asymptomatic individuals are mounting a  
8 normal innate (17), but a weak adaptive antiviral immunity (14). Since antibody titers and  
9 frequency of SARS-CoV-2-specific T cells in the blood can undergo dynamic changes after viral  
10 clearance (10), we reasoned that a proper quantitative comparison between SARS-CoV-2-specific  
11 T cells of symptomatic and asymptomatic individuals should be performed at similar timepoints  
12 post infection. The absence of symptoms makes such evaluation difficult. We therefore selected  
13 85 asymptomatic individuals, from a cohort of individuals living in densely populated dormitories  
14 with active spread of SARS-CoV-2 infection (Fig 1A), who, based on their kinetics of appearance  
15 and disappearance of antibodies against NP and Spike, were likely exposed to SARS-CoV-2 at  
16 different timepoints. In these individuals, we measured directly ex vivo the quantity of IFN- $\gamma$   
17 producing T cells reactive to peptide pools covering different structural proteins (M, NP and Spike)  
18 and compared it to the T cell magnitude detected in symptomatic patients who were infected with  
19 SARS-CoV-2 at similar timepoints.

20 We also evaluated, in both symptomatic and asymptomatic individuals, the functional profile of  
21 SARS-CoV-2-specific T cells. We designed a test to quantify secretion of IL-2, IFN- $\gamma$ , IL-4, IL-6,  
22 IL-12p70, TNF- $\alpha$ , IL-1 $\beta$  and IL-10 directly in whole blood after T cell activation with peptide  
23 pools covering the different SARS-CoV-2 proteins. This experimental system not only measures

1 the quantity of T cell cytokines (IL-2, IL-4, IFN- $\gamma$ ) directly secreted by SARS-CoV-2-specific T  
2 cells but can provide a direct evaluation of the T cells' ability to activate inflammatory or  
3 regulatory pathways in other circulating immune cells. Our results provide experimental evidence  
4 that asymptomatic individuals mount a virus-specific T cell response that is indistinguishable from  
5 symptomatic patients in magnitude, but that is functionally more fit, being characterized by an  
6 augmented secretion of Th1 cytokines (IFN- $\gamma$  and IL-2) associated with a proportionate and  
7 coordinated production of pro- (IL-6, TNF- $\alpha$ , IL-1 $\beta$ ) and anti-inflammatory (IL-10) cytokines. The  
8 implications of these findings for pathology and vaccine designs are discussed.

9

## 10 **Results**

### 11 *Longitudinal serology in asymptomatic SARS-CoV-2 infection*

12 From April 2020, Singapore experienced large outbreaks of SARS-CoV-2 infections  
13 among migrant workers residing in densely populated dormitories (Fig 1A). In order to select  
14 asymptomatic individuals who were exposed to SARS-CoV-2 at different timepoints, we  
15 followed-up 478 residents of a SARS-CoV-2 affected dormitory, who donated blood  
16 at recruitment, and 2 and 6 weeks later for serological testing of anti-nucleoprotein (NP) IgG and  
17 neutralizing antibodies (nAb) (Fig 1B). At recruitment, 131 of the 478 (27.4%) participants were  
18 seropositive by either assay, with 6 (4.6%) reporting COVID-19 compatible symptoms in the  
19 preceding 4 weeks (Fig 2A). Over the 6-week follow-up, 171 of 347 (49.3%) initially seronegative  
20 individuals seroconverted by either assay, demonstrating ongoing exposure to SARS-CoV-2  
21 infection. Only 15 (5.5%) individuals reported symptoms, generally mild, during the follow-up  
22 period. The majority of seropositive individuals (281/302; 93%) were asymptomatic. Individuals  
23 with symptoms were subsequently excluded from this study (Fig 1B).

1 Kinetics of anti-NP IgG and of surrogate virus RBD neutralizing antibodies (sVNT-nAb) (18) in  
2 the asymptomatic study participants are shown in figure 2. Overall, there was a strong correlation  
3 between titers of anti-NP IgG and % of inhibition by sVNT-nAb (Fig 2B). However, at all  
4 timepoints, a higher percentage of asymptomatic donors was positive for sVNT-nAb (30.9%, 47.0%  
5 and 65.4% at recruitment, weeks 2 and 6, respectively) compared with anti-NP IgG (24.4%, 34.6%  
6 and 47.5%) (Fig 2A). Among the 106 individuals with positive anti-NP IgG levels at recruitment,  
7 27 (25.5%) lost them during the six weeks (Fig 2B, C). In contrast, of the 134 participants who  
8 were seropositive for sVNT-nAb at baseline, only 12 (9.0%) became negative over the same time  
9 period (Fig S1).

10

#### 11 *Virus-specific T cell quantification in asymptomatic SARS-CoV-2-exposed donors*

12 To investigate SARS-CoV-2-specific T cells at the 6-week timepoint, which corresponds  
13 to 3 months after the first confirmed case in this dormitory, we selected, among the 434  
14 asymptomatic study participants, 85 individuals with distinct antibody profiles (Fig 2C, D). Fifty-  
15 seven were anti-NP IgG positive at recruitment. Of these, 33 individuals remained persistently  
16 anti-NP IgG positive during the 6-week follow-up, while in 24 the antibody decreased below the  
17 limit of assay detection. We then selected 28 individuals who were seronegative at recruitment. Of  
18 these, 15 became anti-NP IgG positive, while 13 were persistently negative.

19 We first analyzed the frequency of cells reactive to three structural proteins of SARS-CoV-2 by  
20 ex vivo IFN- $\gamma$ -ELISpot assays (Fig 3A). We designed pools of 15-mer peptides covering the whole  
21 NP and M proteins and a selected peptide pool of 15-mers covering the most T cell immunogenic  
22 regions of S (Fig 3A, Fig S2). As previously shown (19), we demonstrate by intracellular cytokine

1 staining that IFN- $\gamma$  was produced by CD4 and CD8 T cells reactive to peptide stimulation, both  
2 directly ex-vivo and after expansion of short-term T cell lines re-stimulated with individual  
3 peptides (Fig S3).

#### 4 *SARS-CoV-2-specific T cells are present in all asymptomatic seropositive individuals*

5 Cells reactive to SARS-CoV-2 peptide-pools were found in all anti-NP IgG positive  
6 individuals regardless of the duration of the antibody persistence (Fig 3B). Moreover, almost all  
7 anti-NP IgG positive individuals had SARS-CoV-2-specific T cells reactive to at least 3 pools  
8 simultaneously, except for 2 (of 24) individuals who had lost anti-NP IgG (Fig 3B). In all groups  
9 with different serology profiles, the M-peptide pool triggered a higher frequency of specific T cells  
10 in comparison to the S and the two NP pools.

11 Among the 13 persistently anti-NP IgG negative participants, 4 had SARS-CoV-2 specific T cells  
12 at a similar frequency as antibody positive participants (Fig 3B, right).

#### 13 *Frequency, multi-specificity and kinetics of SARS-CoV-2-specific cellular immunity in* 14 *symptomatic and asymptomatic infection*

15 Next, we compared the SARS-CoV-2-specific T cell response of the asymptomatic cohort  
16 with the response in a cohort of hospitalized COVID-19 patients with mild to severe symptoms  
17 (Table S1). Within the first 3 months post viral exposure, the frequency of virus-specific T cells  
18 reactive to M, NP and S peptides was similar between symptomatic COVID-19 patients and  
19 asymptotically-infected individuals, and both groups showed a higher frequency of M-pool-  
20 reactive T cells over other pools (Fig 4A). Importantly, nearly all COVID-19 patients and  
21 asymptomatic individuals with serological evidence of infection had T cells recognizing at least 3  
22 peptide pools (Fig 4B).

1 In contrast, the pattern of cross-reactive SARS-CoV-2-specific T cells in archived samples from  
2 SARS-CoV-2 unexposed individuals was different. The overall frequency was lower (10 to 100  
3 spots per  $10^6$  PBMC) and where SARS-CoV-2-peptide reactive T cells were present (20 of 51)  
4 they mostly reacted to a single peptide pool (Fig 4A/B). Only 1 of 51 unexposed individuals tested  
5 had T cells specific for 3 peptide pools.

6 To investigate whether virus-specific T cells undergo clonal reduction over time, we compared  
7 their strength and peptide pool specificity in individuals who seroconverted to anti-NP IgG positive  
8 within the previous 4 weeks, individuals who seroconverted more than 6 weeks previously, and in  
9 initially seropositive individuals who became anti-NP IgG negative. The frequency of SARS-CoV-  
10 2-specific T cells was higher in recent seroconverters (anti-NP-IgG+ <4 weeks) than in those  
11 infected at an earlier time point (Fig 4C, D). Among those who became anti-NP IgG negative, the  
12 frequency of SARS-CoV-2-specific T cells was lower.

13 A decline in the frequency of SARS-CoV-2-specific T cells was also apparent from serial cross-  
14 sectional samples of COVID-19 patients from the acute phase over a period of 7 months post viral  
15 clearance (Fig 4E, F). Over time, some patients lost T cells specific to individual peptide pools,  
16 but M-specific T cells were maintained in all symptomatic and asymptomatic donors tested (Fig  
17 4D, F).

18 Since there was a progressive reduction of SARS-CoV-2-specific T cells over time in all exposed  
19 individuals, we compared the kinetics of their decline between the asymptomatic and symptomatic  
20 cohorts. Among the recent seroconverters (<4 weeks), the frequency of SARS-CoV-2-specific T  
21 cells was comparable with that in symptomatic COVID-19 patients tested during infection and  
22 within 1 month post viral clearance (Fig 4G, left). However, the asymptomatic donors that had  
23 been exposed to SARS-CoV-2 about 2-3 months earlier (anti-NP+ >6 weeks earlier, first



1 confirmed case 3 months earlier) showed a reduced frequency of SARS-CoV-2-specific T cells  
2 compared to patients who recovered from symptomatic infection 2-3 months earlier (Fig 4G,  
3 middle). Thus, the frequency of SARS-CoV-2-specific T cells declines faster after asymptomatic  
4 infection, and within 2-3 months reaches the levels detected in symptomatic patients found at 4-7  
5 months post infection (Fig 4G, right).

6 *The pattern of cytokines induced by SARS-CoV-2-specific T cell activation in symptomatic and*  
7 *asymptomatic infection*

8 In order to functionally define the antiviral cellular immune response present in  
9 asymptomatic and symptomatic SARS-CoV-2 infected individuals, we designed an assay where  
10 the level of Th1 (IFN- $\gamma$ , IL-2, TNF- $\alpha$ ), Th2 (IL-4), pro-inflammatory (IL-6, IL-1 $\beta$ , IL-12p70) and  
11 regulatory (IL-10) cytokines was tested directly in whole blood after overnight stimulation with  
12 SARS-CoV-2 peptide pools (Fig 5A). Cytokines secreted during overnight stimulation can either  
13 be produced by the activation of virus-specific T cells directly, or indirectly by other cell types  
14 that respond to the activation of antigen-specific T cells (Fig S4).

15 We used UMAP (Uniform Manifold Approximation and Projection) for unsupervised dimension  
16 reduction and clustering (20) of the secretoms of all peptide-stimulated samples after subtraction  
17 of cytokine levels present in corresponding DMSO controls (Fig 5B). This showed that secretion  
18 of cytokines classically produced by T cells, IFN- $\gamma$  and IL-2, was overlapping. Moreover, IL-6  
19 and IL-1 $\beta$  were co-secreted, as well as TNF- $\alpha$  and IL-10. IL-12p70 and IL-4 were undetectable in  
20 most samples. While stimulation of blood from unexposed donors did not induce any secretion of  
21 cytokines, the secretoms of SARS-CoV-2 infected donors differed between symptomatic and  
22 asymptomatic infection (Fig 5C). The majority of samples from asymptomatic donors co-secreted  
23 high levels of IFN- $\gamma$  and IL-2, while the samples of symptomatic donors produced low levels of

1 IFN- $\gamma$  and IL-2. A subset of samples from symptomatic donors, enriched for those with severe  
2 disease, clustered with high levels of IL-6, TNF- $\alpha$ , IL-1 $\beta$  and IL-10 secretion (Fig 5C).

3 For the individuals with asymptomatic SARS-CoV-2 infection, we used the appearance,  
4 persistence and decline of anti-NP IgG levels as a proxy for time since infection. This distinguishes  
5 patients with recent infection (<4 weeks anti-NP IgG+) from those who were infected at earlier  
6 timepoints and allowed us to compare them with symptomatic patients that cleared the virus within  
7 the last 4 weeks. Strikingly, the cytokine profile between these two recently infected symptomatic  
8 and asymptomatic groups completely separated by UMAP (Fig 5D left, 5E left). Samples from  
9 recently infected asymptomatic individuals all co-secreted high levels of IFN- $\gamma$  (median = 292  
10 pg/mL) and IL-2 (median = 250 pg/mL), and intermediate levels of IL-6, TNF- $\alpha$ , IL-1 $\beta$  and IL-10.  
11 In contrast, samples from recently infected symptomatic donors co-secreted low levels of IFN- $\gamma$   
12 (median = 35 pg/mL) and IL-2 (median = 45 pg/mL), and a subset co-secreted very high levels of  
13 IL-6, TNF- $\alpha$ , IL-1 $\beta$  and IL-10 (Fig 5D, E, F).

14 Next, we correlated the cytokine levels secreted by peptide stimulation of whole blood with the  
15 frequency of IFN- $\gamma$  spot forming cells detected by ELISpot assay in response to the same peptide  
16 pools (Fig 6). The secretion levels of IFN- $\gamma$  and IL-2 induced by peptide stimulated samples  
17 correlated ( $p < 0.0001$ ) with the number of IFN- $\gamma$  spots in both asymptomatic and symptomatic  
18 individuals, but higher levels of both cytokines in relation to the number of spots were detected in  
19 asymptomatic individuals.

20 In addition, levels of secreted pro-inflammatory (IL-6, TNF- $\alpha$ , IL-1 $\beta$ ) and regulatory (IL-10)  
21 cytokines correlated strongly with the number of IFN- $\gamma$  spots in asymptomatic individuals (Fig  
22 6A). In some symptomatic patients, high levels of IL-6, TNF- $\alpha$ , IL-1 $\beta$  and IL-10 were produced  
23 but were uncorrelated with the number of spots detected in the ELISpot assays (Fig 6B).

1

## 2 **Discussion**

3 Despite their ability to efficiently control the infection, asymptomatic individuals who clear SARS-  
4 CoV-2 have been hypothesized to mount a reduced antiviral adaptive immune response (14). This  
5 hypothesis is supported mainly by measurement of SARS-CoV-2 specific antibodies (14, 21, 22)  
6 and B cell quantity (23).

7 Our study shows clearly that the ability to mount a significant virus-specific T cell response is not  
8 necessarily associated with symptom severity. Our results demonstrate that the overall magnitude  
9 of T cell responses against different structural proteins was similar in both asymptomatic  
10 individuals and COVID-19 patients. Moreover, the T cells induced by an asymptomatic infection  
11 appear to secrete higher quantities of IFN- $\gamma$  and IL-2 and trigger a more coordinated production of  
12 pro-inflammatory and regulatory cytokines than T cells of symptomatic COVID-19 patients.  
13 Overall, we conclude that asymptomatic SARS-CoV-2 infected individuals are able to raise an  
14 efficient and balanced anti-viral cellular immunity which protects the host without causing any  
15 apparent pathology.

16 One of the principal characteristics of our study was in the ability to select, through a 6-week  
17 longitudinal serological study, asymptomatic individuals in whom the time of viral exposure could  
18 be reasonably estimated. The first confirmed SARS-CoV-2 infection in this dormitory was  
19 identified in mid-April 2020, so asymptomatic, seropositive individuals in our cohort were  
20 unlikely to have been infected more than 3 months before sampling (performed in mid-July 2020)  
21 (Fig 1A). More importantly, by evaluating the period of SARS-CoV-2 antibody seroconversion,

1 we could separate individuals who were likely infected more than 6 weeks before sampling from  
2 those who were likely infected within the last 4 weeks.

3 The ability to estimate the time of infection allowed us to compare the magnitude and function of  
4 SARS-CoV-2-specific T cells present in asymptotically-infected individuals with those of  
5 COVID-19 patients at similar timepoints during and after infection. We demonstrated that all  
6 asymptomatic individuals capable of producing anti-SARS-CoV-2 antibodies also mount a T cell  
7 response that simultaneously targets different structural proteins of SARS-CoV-2 (NP, M and S).  
8 In addition, we observed that, similarly to COVID-19 recovered patients, SARS-CoV-2-specific  
9 T cell frequency in asymptomatic individuals declined progressively over time. Surprisingly, more  
10 recently infected asymptomatic individuals possess a SARS-CoV-2-specific T cell frequency of  
11 indistinguishable magnitude to the one detected in COVID-19 patients (mild, moderate and severe)  
12 tested during acute infection (SARS-CoV-2 PCR positive) or within 1 month after viral clearance.  
13 This finding further supports the accumulating evidence that the quantity of SARS-CoV-2-specific  
14 T cells is not proportional to disease severity during the early phase of infection (*9, 10*). This is in  
15 contrast to the positive correlation between SARS-CoV-2-specific T cell frequency and  
16 presence/severity of symptoms reported by others. In those studies, however, SARS-CoV-2-  
17 specific T cell responses were evaluated several months after recovery (*15, 16, 24, 25*).

18 We further show that despite a similar magnitude of virus-specific T cells induced in asymptomatic  
19 and symptomatic infection, SARS-CoV-2-specific T cells seem to decline faster in asymptomatic  
20 individuals. SARS-CoV-2-specific T cell frequency detected 2-3 months after asymptomatic  
21 infection was lower than that detected in COVID-19 patients at similar time after infection and  
22 identical to what was detected in COVID-19 recovered individuals 6 months after infection. A  
23 more extended study of the persistence of SARS-CoV-2-specific T cells in our asymptomatic

1 cohort is needed to confirm such a trend. Nevertheless, at this moment our data suggest that the  
2 recently reported higher frequency of SARS-CoV-2-specific T cells in COVID-19 recovered  
3 patients in comparison to asymptomatic individuals 6 months after recovery, might not be caused  
4 by a higher set point present during the early phases of infection as suggested (24). An alternative  
5 explanation could be that SARS-CoV-2-specific T cells persist longer at a higher frequency in  
6 COVID-19 recovered patients, since viral antigen might persist more in symptomatic patients who  
7 usually have higher quantity of viral replication (26). The recent observation that SARS-CoV-2-  
8 specific B cells progressively evolved after COVID-19 recovery due to the presence of SARS-  
9 CoV-2 antigen in the small bowel (27), makes such hypothesis even more plausible.

10 Finally, we also show that asymptomatic SARS-CoV-2 infected individuals mount an efficient  
11 anti-viral cellular immunity, by analyzing the quantity of cytokines secreted in whole blood after  
12 pulsing with different SARS-CoV-2 peptide pools and by correlating this quantity with the number  
13 of spots detected in our ELISpot analysis. We utilized this relatively simple approach for several  
14 reasons. In our study, we wanted to prioritize a direct ex vivo analysis of the T cell response in  
15 fresh blood rather than in frozen PBMC, since freezing and thawing can reduce the detection of  
16 CD4 T cell responses (28) that represent the majority of virus-specific T cells in SARS-CoV-2  
17 infection (19, 29). We also wanted to analyze the global impact that T cell activation might have  
18 on other immune cells, particularly of the myeloid compartment, which is known to contribute  
19 substantially to the inflammatory reactions associated with SARS-CoV-2 infection (3, 30, 31).  
20 Clearly, this whole blood cytokine assay has limitations, since it does not enable distinction of the  
21 cellular source of the different cytokines. However, it provides a holistic snapshot of the virus-  
22 specific cellular immunity and can be performed in a large group of asymptomatic individuals  
23 tested in a limited time. The results obtained with unsupervised clustering were extremely clear in

1 describing distinct cytokine secretion patterns in symptomatic versus asymptomatic individuals  
2 and revealed possible features of SARS-CoV-2-specific T cell responses that are worthy of more  
3 detailed characterization in future studies.

4 We observed a high secretion of TNF- $\alpha$ , IL-6, IL-1 $\beta$  and IL-10 exclusively in the blood of a subset  
5 of patients who recently recovered from COVID-19, especially in patients with severe COVID-19.  
6 The high secretion of pro-inflammatory cytokines was, however, neither proportional to the  
7 quantity of IFN- $\gamma$  and IL-2 detected in the same assay nor to the number of IFN- $\gamma$  spots detected  
8 in the same patients analyzed in parallel with ELISpot. These findings seem to confirm that  
9 myeloid cells present in patients who recovered from symptomatic COVID-19 disease have been  
10 reprogrammed to promote inflammatory signals and are hyper-responsive to IFNs (30).

11 Secretion of the pro-inflammatory cytokines IL-6, TNF- $\alpha$ , IL-1 $\beta$  was also detected in peptide-  
12 stimulated blood of asymptomatic individuals. Yet, their quantity was directly proportional to the  
13 quantity of T cell cytokines (IL-2, IFN- $\gamma$ ). Surprisingly, the quantity of IL-2 and IFN- $\gamma$  was much  
14 higher in asymptomatic individuals than in COVID-19 recovered patients. Moreover, the close  
15 correlation of IFN- $\gamma$  spots and cytokine production detected in the same experiments strongly  
16 suggests that T cells of asymptomatic individuals are endowed with a higher IFN- $\gamma$  and IL-2  
17 production capacity than the T cells of COVID-19 recovered patients.

18 To our knowledge, these are the first data to show, through direct comparison, that SARS-CoV-2-  
19 specific cellular immune responses are more efficient in asymptomatic than symptomatic  
20 individuals. Previous results are supporting our findings: a low IFN- $\gamma$  production of total (32) and  
21 SARS-CoV-2-specific T cells (33) has been reported in COVID-19 patients, while conversely,  
22 high quantity of IFN- $\gamma$  RNA was found in CD4 T cells of asymptomatic individuals (17).

1 Finally, we detected production of IL-10 proportional to T cell cytokines (IL-2 and IFN- $\gamma$ ) and to  
2 the numbers of spots activated by similar SARS-CoV-2 peptide activation only in asymptomatic  
3 individuals. Unfortunately, technical challenges (low quantity of IL-10 secretion by T cells, lack  
4 of fresh blood of asymptomatic subjects recently infected) has so far precluded the direct  
5 visualization of IL-10 production by T cells and not by other cell types (B cells, monocytes) known  
6 to secrete IL-10 (34). In conclusion, the overall picture of SARS-CoV-2-specific cellular immune  
7 responses detected by a combination of two different functional assays shows that patients with  
8 asymptomatic infection mount a coordinated and balanced activation of virus-specific T cells able  
9 to trigger a production of high quantities of IFN- $\gamma$  and IL-2 linked with secretion of IL-10. Animal  
10 models have already shown that the ability of T cells to secrete IFN- $\gamma$  and IL-10 simultaneously  
11 led to an effective viral control without triggering pathological processes (12, 35). We suggest that  
12 this could be the functional signature of protective virus-specific cellular immune responses in  
13 asymptomatic SARS-CoV-2 infection. A detailed analysis at single cell level of the functional  
14 profile of SARS-CoV-2-specific T cells in symptomatically and asymptotically infected  
15 individuals will be needed to formally demonstrate such hypothesis.

16

## 17 **Materials and Methods**

### 18 *Ethics statement*

19 The study of migrant workers was approved by the Singapore Ministry of Health under Section  
20 59A of the Infectious Diseases Act (2015), thus institutional review board approval was not  
21 required and all participants gave verbal consent to participate. All COVID-19 patients provided  
22 written informed consent and their study was approved by the Institutional Review Boards of NUS

1 (H-20-006), SingHealth (CIRB/F/2018/2387 and CIRB/F/2018/3045) and the National Healthcare  
2 Group Domain Specific Review Board (2012/00917).

### 3 *Study population*

4 The asymptomatic cohort comprised 541 men aged 19-59 years (median 35 years) recruited from  
5 randomly-selected rooms within a SARS-CoV-2 affected dormitory housing over 4000 migrant  
6 workers and followed up prospectively from May to July 2020. Of these, 478 (88.4%) participants  
7 provided blood samples at recruitment, and at 2 and 6 weeks (Fig 1). Participants also declared  
8 symptoms at the time of blood draws and their information was cross-checked with the medical  
9 post based in the dormitory. At the 6-week follow-up, a subset of 85 asymptomatic participants  
10 provided an additional blood sample for assessment of cell-mediated immune responses.  
11 Participants were not tested for infection by polymerase chain reaction (PCR), because at the time  
12 of the study, testing of asymptomatic individuals without clinical indication was not recommended.  
13 For hospitalized symptomatic patients, blood samples were obtained from the PCR positivity phase  
14 till 193 days post PCR negativity from recovered COVID-19 patients (n=76; n=16 were sampled  
15 longitudinally; Table S1). All archived healthy donors' samples were collected before June 2019.

### 16 *Antibody quantification*

17 Sera were tested for anti-nucleoprotein (NP) IgG antibodies (CMIA, Abbott Laboratories) on an  
18 Abbott Architect i2000SR automated instrument; a signal to cutoff ratio of  $\geq 1.4$  was defined as a  
19 positive result following the manufacturer's recommendation. A second serum aliquot was tested  
20 with a surrogate virus neutralization test that detects isotype-independent RBD neutralizing  
21 antibodies (cPass, GenScript) (18). Based on the manufacturer's instructions, a virus inhibition  
22 threshold of  $\geq 20\%$  was considered a positive result.



## 1 *SARS-CoV-2-specific T cell quantification*

2 SARS-CoV-2-specific T cells were tested as described before (19). Briefly, peripheral blood  
3 mononuclear cells (PBMC) were isolated using Ficoll-Paque and directly tested by IFN- $\gamma$ -ELISpot  
4 for reactivity to 4 SARS-CoV-2 peptide pools of 15-mers covering NP (NP-1, NP-2) and  
5 membrane (M), and one pool of 55 peptides covering the most immunogenic regions of Spike (S)  
6 (Fig S2). ELISpot plates (Millipore) were coated with human IFN- $\gamma$  antibody (1-D1K, Mabtech)  
7 overnight at 4°C. 400,000 PBMC were seeded per well and stimulated for 18h with pools of SARS-  
8 CoV-2 peptides (2  $\mu$ g/ml). For stimulation with peptide matrix pools or single peptides, a  
9 concentration of 5  $\mu$ g/ml was used. Subsequently, the plates were developed with human  
10 biotinylated IFN- $\gamma$  detection antibody (7-B6-1, Mabtech), followed by incubation with  
11 Streptavidin-AP (Mabtech) and KPL BCIP/NBT Phosphatase Substrate (SeraCare). To quantify  
12 positive peptide-specific responses, 2x mean spots of the unstimulated wells were subtracted from  
13 the peptide-stimulated wells, and the results expressed as spot forming cells (SFC)/10<sup>6</sup> PBMC. We  
14 excluded the results if negative control wells had >30 SFC/10<sup>6</sup> PBMC or positive control wells  
15 (PMA/Ionomycin) were negative.

## 16 *Cell culture for T cell expansion*

17 T cell lines were generated as follows: 20% of PBMCs were pulsed with 10  $\mu$ g/ml of the  
18 overlapping SARS-CoV-2 peptides for 1 hour at 37°C, subsequently washed, and cocultured with  
19 the remaining cells in AIM-V medium (Gibco; Thermo Fisher Scientific) supplemented with 2%  
20 AB human serum (Gibco; Thermo Fisher Scientific). T cell lines were cultured for 10 days in the  
21 presence of 20 U/ml of recombinant IL-2 (R&D Systems).

## 22 *Flow cytometry*

1 PBMC or expanded T cell lines were stimulated for 5h (or 7h) at 37°C with or without SARS-  
2 CoV-2 peptide pools (2 µg/ml). After 1h (or 3h,) 10 µg/ml brefeldin A (Sigma-Aldrich) and 1x  
3 monensin (Biolegend) were added. Cells were stained with the yellow LIVE/DEAD fixable dead  
4 cell stain kit (Invitrogen) and surface marker: anti-CD3 (SK7 or OKT3, Biolegend), anti-CD4  
5 (SK3), anti-CD8 (SK1), anti-CD14 (TUK4, Miltenyi Biotec), anti-CD16 (3G8, Biolegend), anti-  
6 CD19 (SJ25-C1), anti-CD56 (HCD56, Biolegend). Cells were subsequently fixed and  
7 permeabilized using the Cytotfix/Cytoperm kit (BD Biosciences-Pharmingen) and stained with  
8 anti-IFN-γ (25723, R&D Systems), anti-IL-2 (MQ1-17H12), anti-IL-6 (MQ2-13A5), anti-IL-10  
9 (JES3-19F1) and anti-TNF-α (MAb11) antibodies and analyzed on a BD-LSR II FACS Scan. Data  
10 were analyzed by FlowJo (BD Biosciences). Antibodies were purchased from BD Biosciences-  
11 Pharmingen unless otherwise stated.

#### 12 *Whole blood culture with SARS-CoV-2 peptide pools*

13 320 µl of whole blood drawn on the same day were mixed with 80 µl RPMI and stimulated with  
14 pools of SARS-CoV-2 peptides (M, NP1, NP2 or S; 2 µg/ml) or a DMSO control. After 15 hours  
15 of culture, the culture supernatant (plasma) was collected and stored at -80°C until quantification  
16 of cytokines.

#### 17 *Cytokine quantification and analysis*

18 Cytokine concentrations in the plasma were quantified using an Ella machine with microfluidic  
19 multiplex cartridges measuring IFN-γ, IL-2, TNF-α, IL-4, IL-6, IL-1β, IL-12p70 and IL-10  
20 following the manufacturer's instructions (ProteinSimple). The level of cytokines present in the  
21 plasma of DMSO controls was subtracted from the corresponding peptide pool stimulated samples.  
22 Subsequently, concentrations of each cytokine in all culture supernatants were transformed using

1 the logicle transformation function and UMAP was run using 15 nearest neighbors (*nn*), a *min\_dist*  
2 of 0.2 and euclidean distance (20). The results obtained from UMAP analyses were incorporated  
3 as additional parameters and converted to .fcs files, which were then loaded into FlowJo to  
4 generate heatmaps of cytokine secretion on the reduced dimensions.

5 *Statistical analysis*

6 All tests are stated in the figure legends. P-values (all two-tailed): <0.5 = \*; <0.01 = \*\*; <0.001 =  
7 \*\*\*; <0.0001 = \*\*\*\*.

## 1 References

- 2 1. S. A. Vardhana, J. D. Wolchok, The many faces of the anti-COVID immune response, *J. Exp.*  
3 *Med.* **217**, 166–10 (2020).
- 4 2. L. Kuri-Cervantes, M. B. Pampena, W. Meng, A. M. Rosenfeld, C. A. G. Ittner, A. R.  
5 Weisman, R. S. Agyekum, D. Mathew, A. E. Baxter, L. A. Vella, O. Kuthuru, S. A. Apostolidis,  
6 L. Bershaw, J. Dougherty, A. R. Greenplate, A. Pattekar, J. Kim, N. Han, S. Gouma, M. E.  
7 Weirick, C. P. Arevalo, M. J. Bolton, E. C. Goodwin, E. M. Anderson, S. E. Hensley, T. K.  
8 Jones, N. S. Mangalmurti, E. T. Luning Prak, E. J. Wherry, N. J. Meyer, M. R. Betts,  
9 Comprehensive mapping of immune perturbations associated with severe COVID-19, *Science*  
10 *Immunology* **5**, eabd7114–20 (2020).
- 11 3. A. Silvin, N. Chapuis, G. Dunsmore, A.-G. Goubet, A. Dubuisson, L. Derosa, C. Almire, C.  
12 Hénon, O. Kosmider, N. Droin, P. Rameau, C. Catelain, A. Alfaro, C. Dussiau, C. Friedrich, E.  
13 Sourdeau, N. Marin, T.-A. Szwebel, D. Cantin, L. Mouthon, D. Borderie, M. Deloger, D. Bredel,  
14 S. Mouraud, D. Drubay, M. Andrieu, A.-S. Lhonneur, V. Saada, A. Stoclin, C. Willekens, F.  
15 Pommeret, F. Griscelli, L. G. Ng, Z. Zhang, P. Bost, I. Amit, F. Barlesi, A. Marabelle, F. Pène,  
16 B. Gachot, F. André, L. Zitvogel, F. Ginhoux, M. Fontenay, E. Solary, Elevated Calprotectin and  
17 Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19, *Cell* **182**, 1401–  
18 1418.e18 (2020).
- 19 4. R. Nienhold, Y. Ciani, V. H. Koelzer, A. Tzankov, J. D. Haslbauer, T. Menter, N. Schwab, M.  
20 Henkel, A. Frank, V. Zsikla, N. Willi, W. Kempf, T. Hoyler, M. Barbareschi, H. Moch, M.  
21 Tolnay, G. Cathomas, F. Demichelis, T. Junt, K. D. Mertz, Two distinct immunopathological  
22 profiles in autopsy lungs of COVID-19, *Nature Communications* **11**, 5086–13 (2020).
- 23 5. A. G. Laing, A. Lorenc, I. del Molino del Barrio, A. Das, M. Fish, L. Monin, M. Muñoz-Ruiz,  
24 D. R. McKenzie, T. S. Hayday, I. Francos-Quijorna, S. Kamdar, M. Joseph, D. Davies, R. Davis,  
25 A. Jennings, I. Zlatareva, P. Vantourout, Y. Wu, V. Sofra, F. Cano, M. Greco, E. Theodoridis, J.  
26 Freedman, S. Gee, J. N. E. Chan, S. Ryan, E. Bugallo-Blanco, P. Peterson, K. Kisand, L.  
27 Haljasmägi, L. Chadli, P. Moingeon, L. Martinez, B. Merrick, K. Bisnauthsing, K. Brooks, M.  
28 A. A. Ibrahim, J. Mason, F. Lopez Gomez, K. Babalola, S. Abdul-Jawad, J. Cason, C. Mant, J.  
29 Seow, C. Graham, K. J. Doores, F. Di Rosa, J. Edgeworth, M. Shankar-Hari, A. C. Hayday, A  
30 dynamic COVID-19 immune signature includes associations with poor prognosis, *Nat Med* **579**,  
31 270–33 (2020).
- 32 6. Q.-X. Long, B.-Z. Liu, H.-J. Deng, G.-C. Wu, K. Deng, Y.-K. Chen, P. Liao, J.-F. Qiu, Y. Lin,  
33 X.-F. Cai, D.-Q. Wang, Y. Hu, J.-H. Ren, N. Tang, Y.-Y. Xu, L.-H. Yu, Z. Mo, F. Gong, X.-L.  
34 Zhang, W.-G. Tian, L. Hu, X.-X. Zhang, J.-L. Xiang, H.-X. Du, H.-W. Liu, C.-H. Lang, X.-H.  
35 Luo, S.-B. Wu, X.-P. Cui, Z. Zhou, M.-M. Zhu, J. Wang, C.-J. Xue, X.-F. Li, L. Wang, Z.-J. Li,  
36 K. Wang, C.-C. Niu, Q.-J. Yang, X.-J. Tang, Y. Zhang, X.-M. Liu, J.-J. Li, D.-C. Zhang, F.  
37 Zhang, P. Liu, J. Yuan, Q. Li, J.-L. Hu, J. Chen, A.-L. Huang, Antibody responses to SARS-  
38 CoV-2 in patients with COVID-19, *Nat Med* **26**, 845–848 (2020).
- 39 7. C. Cervia, J. Nilsson, Y. Zurbuchen, A. Valaperti, J. Schreiner, A. Wolfensberger, M. E.  
40 Raeber, S. Adamo, M. Emmenegger, S. Hasler, P. P. Bosshard, E. De Cecco, E. Bächli, A.

- 1 Rudiger, M. Stüssi-Helbling, L. C. Huber, A. S. Zinkernagel, D. J. Schaer, A. Aguzzi, U. Held,  
2 E. Probst-Müller, S. K. Rampini, O. Boyman, Systemic and mucosal antibody secretion specific  
3 to SARS-CoV-2 during mild versus severe COVID-19, *bioRxiv* doi: 2020.05.21.108308 (2020).
- 4 8. D. Weiskopf, K. S. Schmitz, M. P. Raadsen, A. Grifoni, N. M. A. Okba, H. Endeman, J. P. C.  
5 van den Akker, R. Molenkamp, M. P. G. Koopmans, E. C. M. van Gorp, B. L. Haagmans, R. L.  
6 de Swart, A. Sette, R. D. de Vries, Phenotype and kinetics of SARS-CoV-2-specific T cells in  
7 COVID-19 patients with acute respiratory distress syndrome, *Science Immunology* **5**, eabd2071  
8 (2020).
- 9 9. C. Rydyznski Moderbacher, S. I. Ramirez, J. M. Dan, A. Grifoni, K. M. Hastie, D. Weiskopf,  
10 S. Belanger, R. K. Abbott, C. Kim, J. Choi, Y. Kato, E. G. Crotty, C. Kim, S. A. Rawlings, J.  
11 Mateus, L. P. V. Tse, A. Frazier, R. Baric, B. Peters, J. Greenbaum, E. Ollmann Saphire, D. M.  
12 Smith, A. Sette, S. Crotty, Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute  
13 COVID-19 and Associations with Age and Disease Severity, *Cell* **183**, 996–1012.e19 (2020).
- 14 10. A. T. Tan, M. Linster, C. W. Tan, N. Le Bert, W. N. Chia, K. Kunasegaran, Y. Zhuang, C. Y.  
15 L. Tham, A. Chia, G. J. Smith, B. Young, S. Kalimuddin, J. G. H. Low, D. Lye, L.-F. Wang, A.  
16 Bertoletti, Early induction of SARS-CoV-2 specific T cells associates with rapid viral clearance  
17 and mild disease in COVID-19 patients, *bioRxiv* doi: 10.1101/2020.10.15.341958 (2020).
- 18 11. J. Zhao, J. Zhao, S. Perlman, T cell responses are required for protection from clinical  
19 disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice,  
20 *Journal of Virology* **84**, 9318–9325 (2010).
- 21 12. J. Zhao, J. Zhao, A. K. Mangalam, R. Channappanavar, C. Fett, D. K. Meyerholz, S.  
22 Agnihothram, R. S. Baric, C. S. David, S. Perlman, Airway Memory CD4 + T Cells Mediate  
23 Protective Immunity against Emerging Respiratory Coronaviruses, *Immunity* **44**, 1379–1391  
24 (2016).
- 25 13. E. Lavezzo, E. Franchin, C. Ciavarella, G. Cuomo-Dannenburg, L. Barzon, C. Del Vecchio,  
26 L. Rossi, R. Manganelli, A. Lorigian, N. Navarin, D. Abate, M. Sciro, S. Merigliano, E. De  
27 Canale, M. C. Vanuzzo, V. Besutti, F. Saluzzo, F. Onelia, M. Pacenti, S. G. Parisi, G. Carretta,  
28 D. Donato, L. Flor, S. Cocchio, G. Masi, A. Sperduti, L. Cattarino, R. Salvador, M. Nicoletti, F.  
29 Caldart, G. Castelli, E. Nieddu, B. Labella, L. Fava, M. Drigo, K. A. M. Gaythorpe, Imperial  
30 College COVID-19 Response Team, A. R. Brazzale, S. Toppo, M. Trevisan, V. Baldo, C. A.  
31 Donnelly, N. M. Ferguson, I. Dorigatti, A. Crisanti, Suppression of a SARS-CoV-2 outbreak in  
32 the Italian municipality of Vo', *Nature* **584**, 425–429 (2020).
- 33 14. Q.-X. Long, X.-J. Tang, Q.-L. Shi, Q. Li, H.-J. Deng, J. Yuan, J.-L. Hu, W. Xu, Y. Zhang,  
34 F.-J. Lv, K. Su, F. Zhang, J. Gong, B. Wu, X.-M. Liu, J.-J. Li, J.-F. Qiu, J. Chen, A.-L. Huang,  
35 Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections, *Nat Med* **63**,  
36 706–12 (2020).
- 37 15. T. Sekine, A. Perez-Potti, O. Rivera-Ballesteros, K. Strålin, J.-B. Gorin, A. Olsson, S.  
38 Llewellyn-Lacey, H. Kamal, G. Bogdanovic, S. Muschiol, D. J. Wullimann, T. Kammann, J.  
39 Emgård, T. Parrot, E. Folkesson, Karolinska COVID-19 Study Group, O. Rooyackers, L. I.  
40 Eriksson, J.-I. Henter, A. Sönnernborg, T. Allander, J. Albert, M. Nielsen, J. Klingström, S.

- 1 Gredmark-Russ, N. K. Björkström, J. K. Sandberg, D. A. Price, H. G. Ljunggren, S. Aleman, M.  
2 Buggert, Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild  
3 COVID-19, *Cell* **183**, 158–168.e14 (2020).
- 4 16. C. J. Reynolds, L. Swadling, J. M. Gibbons, C. Pade, M. Jensen, M. O. Diniz, N. M.  
5 Schmidt, D. K. Butler, O. E. Amin, S. N. L. Bailey, S. Talyor, J. Jones, M. Jones, W. Y. J. Lee,  
6 J. Rosenheim, A. Chandran, G. Joy, C. Di Genova, N. J. Temperton, J. Lambourne, T. Cutino-  
7 Moguel, M. Andiapen, M. Fontana, A. Smit, A. Semper, B. O'Brien, B. Chain, T. Brooks, C.  
8 Manisty, T. Treibel, J. Moon, COVIDsortium Investigators, M. C. Noursadeghi, COVIDsortium  
9 Immune correlates network, D. M. Altmann, M. K. Mani, A. McKnight, R. J. Boyton, Healthcare  
10 workers with mild / asymptomatic SARS-CoV-2 infection show T cell responses and  
11 neutralising antibodies after the first wave, *medRxiv* doi: 0.1101/2020.10.13.20211763 (2020).
- 12 17. X.-N. Zhao, Y. You, G.-L. Wang, H.-X. Gao, X.-M. Cui, L.-J. Duan, S.-B. Zhang, Y.-L.  
13 Wang, Lin-Yao, L. Li, J.-H. Lu, H.-B. Wang, J.-F. Fan, H.-W. Zheng, E.-H. Dai, L.-Y. Tian, M.-  
14 J. Ma, Longitudinal single-cell immune profiling revealed distinct innate immune response in  
15 asymptomatic COVID-19 patients, *bioRxiv* doi: 10.1101/2020.09.02.276865 (2020).
- 16 18. C. W. Tan, W. N. Chia, X. Qin, P. Liu, M. I.-C. Chen, C. Tiu, Z. Hu, V. C.-W. Chen, B. E.  
17 Young, W. R. Sia, Y.-J. Tan, R. Foo, Y. Yi, D. C. Lye, D. E. Anderson, L.-F. Wang, A SARS-  
18 CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike  
19 protein-protein interaction, *Nat Biotechnol* **39**, 470–6 (2020).
- 20 19. N. Le Bert, A. T. Tan, K. Kunasegaran, C. Y. L. Tham, M. Hafezi, A. Chia, M. H. Y. Chng,  
21 M. Lin, N. Tan, M. Linster, W. N. Chia, M. I.-C. Chen, L.-F. Wang, E. E. Ooi, S. Kalimuddin, P.  
22 A. Tambyah, J. G.-H. Low, Y.-J. Tan, A. Bertoletti, SARS-CoV-2-specific T cell immunity in  
23 cases of COVID-19 and SARS, and uninfected controls, *Nature* **584**, 457–462 (2020).
- 24 20. E. Becht, L. McInnes, J. Healy, C.-A. Dutertre, I. W. H. Kwok, L. G. Ng, F. Ginhoux, E. W.  
25 Newell, Dimensionality reduction for visualizing single-cell data using UMAP, *Nat Biotechnol*  
26 **37**, 38–44 (2018).
- 27 21. C. Atyeo, S. Fischinger, T. Zohar, M. D. Slein, J. Burke, C. Loos, D. J. McCulloch, K. L.  
28 Newman, C. Wolf, J. Yu, K. Shuey, J. Feldman, B. M. Hauser, T. Caradonna, A. G. Schmidt, T.  
29 J. Suscovich, C. Linde, Y. Cai, D. Barouch, E. T. Ryan, R. C. Charles, D. Lauffenburger, H.  
30 Chu, G. Alter, Distinct Early Serological Signatures Track with SARS-CoV-2 Survival,  
31 *Immunity* **53**, 524–532.e4 (2020).
- 32 22. L. Henss, T. Scholz, C. von Rhein, I. Wieters, F. Borgans, F. J. Eberhardt, K. Zacharowski,  
33 S. Ciesek, G. Rohde, M. Vehreschild, C. Stephan, T. Wolf, H. Hofmann-Winkler, H.  
34 Scheiblauer, B. S. Schnierle, Analysis of humoral immune responses in SARS-CoV-2 infected  
35 patients, *The Journal of Infectious Diseases* doi: 10.1093/infdis/jiaa680 (2020).
- 36 23. M. C. Woodruff, R. P. Ramonell, D. C. Nguyen, K. S. Cashman, A. S. Saini, N. S. Haddad,  
37 A. M. Ley, S. Kyu, J. C. Howell, T. Ozturk, S. Lee, N. Suryadevara, J. B. Case, R. Bugrovsky,  
38 W. Chen, J. Estrada, A. Morrison-Porter, A. Derrico, F. A. Anam, M. Sharma, H. M. Wu, S. N.  
39 Le, S. A. Jenks, C. M. Tipton, B. Staitieh, J. L. Daiss, E. Ghosn, M. S. Diamond, R. H.

- 1 Carnahan, J. E. Crowe, W. T. Hu, F. E.-H. Lee, I. Sanz, Extrafollicular B cell responses correlate  
2 with neutralizing antibodies and morbidity in COVID-19, *Nat Immunol* **21**, 1506–16 (2020).
- 3 24. J. Zuo, A. Dowell, H. Pearce, K. Verma, H. M. Long, J. Begum, F. Aiano, Z. Amin-  
4 Chowdhury, B. Hallis, L. Stapley, R. Borrow, E. Linley, S. Ahmad, B. Parker, A. Horsley, G.  
5 Amirthalingam, K. Brown, M. E. Ramsay, S. Ladhani, P. Moss, Robust SARS-CoV-2-specific  
6 T-cell immunity is maintained at 6 months following primary infection, *bioRxiv* doi:  
7 0.1101/2020.11.01.362319 (2020).
- 8 25. Y. Peng, A. J. Mentzer, G. Liu, X. Yao, Z. Yin, D. Dong, W. Dejnirattisai, T. Rostron, P.  
9 Supasa, C. Liu, C. Lopez-Camacho, J. Slon-Campos, Y. Zhao, D. I. Stuart, G. C. Paesen, J. M.  
10 Grimes, A. A. Antson, O. W. Bayfield, D. E. D. P. Hawkins, D.-S. Ker, B. Wang, L. Turtle, K.  
11 Subramaniam, P. Thomson, P. Zhang, C. Dold, J. Ratcliff, P. Simmonds, T. de Silva, P. Sopp, D.  
12 Wellington, U. Rajapaksa, Y.-L. Chen, M. Salio, G. Napolitani, W. Paes, P. Borrow, B. M.  
13 Kessler, J. W. Fry, N. F. Schwabe, M. G. Semple, J. K. Baillie, S. C. Moore, P. J. M. Openshaw,  
14 M. A. Ansari, S. Dunachie, E. Barnes, J. Frater, G. Kerr, P. Goulder, T. Lockett, R. Levin, Y.  
15 Zhang, R. Jing, L.-P. Ho, Oxford Immunology Network Covid-19 Response T cell Consortium,  
16 ISARIC4C Investigators, R. J. Cornall, C. P. Conlon, P. Klenerman, G. R. Screaton, J.  
17 Mongkolsapaya, A. McMichael, J. C. Knight, G. Ogg, T. Dong, Broad and strong memory  
18 CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following  
19 COVID-19, *Nat Immunol* **21**, 1336–1345 (2020).
- 20 26. Y. Wang, L. Zhang, L. Sang, F. Ye, S. Ruan, B. Zhong, T. Song, A. N. Alshukairi, R. Chen,  
21 Z. Zhang, M. Gan, A. Zhu, Y. Huang, L. Luo, C. K. P. Mok, M. M. Al Gethamy, H. Tan, Z. Li,  
22 X. Huang, F. Li, J. Sun, Y. Zhang, L. Wen, Y. Li, Z. Chen, Z. Zhuang, J. Zhuo, C. Chen, L.  
23 Kuang, J. Wang, H. Lv, Y. Jiang, M. Li, Y. Lin, Y. Deng, L. Tang, J. Liang, J. Huang, S.  
24 Perlman, N. Zhong, J. Zhao, J. S. Malik Peiris, Y. Li, J. Zhao, Kinetics of viral load and antibody  
25 response in relation to COVID-19 severity, *J. Clin. Invest.* **130**, 5235–5244 (2020).
- 26 27. C. Gaebler, Z. Wang, J. C. C. Lorenzi, F. Muecksch, S. Finkin, M. Tokuyama, M. Ladinsky,  
27 A. Cho, M. Jankovic, D. Schaefer-Babajew, T. Y. Oliveira, M. Cipolla, C. Viant, C. O. Barnes,  
28 A. Hurley, M. Turroja, K. Gordon, K. G. Millard, V. Ramos, F. Schmidt, Y. Weisblum, D. Jha,  
29 M. Tankelevich, J. Yee, I. Shimeliovich, D. F. Robbiani, Z. Zhao, A. Gazumyan, T.  
30 Hatzioannou, P. J. Bjorkman, S. Mehandru, P. D. Bieniasz, M. Caskey, M. C. Nussenzweig,  
31 Evolution of Antibody Immunity to SARS-CoV-2, *bioRxiv* doi: 10.1101/2020.11.03.367391  
32 (2020).
- 33 28. T. Ford, C. Wenden, A. Mbekeani, L. Dally, J. H. Cox, M. Morin, N. Winstone, A. V. S.  
34 Hill, J. Gilmour, K. J. Ewer, Cryopreservation-related loss of antigen-specific IFN $\gamma$  producing  
35 CD4+ T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine  
36 trial substudy, *Vaccine* **35**, 1898–1906 (2017).
- 37 29. A. Grifoni, D. Weiskopf, S. I. Ramirez, J. Mateus, J. M. Dan, C. R. Moderbacher, S. A.  
38 Rawlings, A. Sutherland, L. Premkumar, R. S. Jadi, D. Marrama, A. M. de Silva, A. Frazier, A.  
39 F. Carlin, J. A. Greenbaum, B. Peters, F. Krammer, D. M. Smith, S. Crotty, A. Sette, Targets of  
40 T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and  
41 Unexposed Individuals, *Cell* **181**, 1489–1501.e15 (2020).

- 1 30. J. S. Lee, S. Park, H. W. Jeong, J. Y. Ahn, S. J. Choi, H. Lee, B. Choi, S. K. Nam, M. Sa, J.-  
2 S. Kwon, S. J. Jeong, H. K. Lee, S. H. Park, S.-H. Park, J. Y. Choi, S.-H. Kim, I. Jung, E.-C.  
3 Shin, Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in  
4 development of severe COVID-19, *Science Immunology* **5**, eabd1554 (2020).
- 5 31. C. Lucas, P. Wong, J. Klein, T. B. R. Castro, J. Silva, M. Sundaram, M. K. Ellingson, T.  
6 Mao, J. E. Oh, B. Israelow, T. Takahashi, M. Tokuyama, P. Lu, A. Venkataraman, A. Park, S.  
7 Mohanty, H. Wang, A. L. Wyllie, C. B. F. Vogels, R. Earnest, S. Lapidus, I. M. Ott, A. J. Moore,  
8 M. C. Muenker, J. B. Fournier, M. Campbell, C. D. Odio, A. Casanovas-Massana, Yale  
9 IMPACT Team, R. Herbst, A. C. Shaw, R. Medzhitov, W. L. Schulz, N. D. Grubaugh, C. Dela  
10 Cruz, S. Farhadian, A. I. Ko, S. B. Omer, A. Iwasaki, Longitudinal analyses reveal  
11 immunological misfiring in severe COVID-19, *Nature* **584**, 463–469 (2020).
- 12 32. S. De Biasi, M. Meschiari, L. Gibellini, C. Bellinazzi, R. Borella, L. Fidanza, L. Gozzi, A.  
13 Iannone, D. Lo Tartaro, M. Mattioli, A. Paolini, M. Menozzi, J. Milić, G. Franceschi, R. Fantini,  
14 R. Tonelli, M. Sita, M. Sarti, T. Trenti, L. Brugioni, L. Cicchetti, F. Facchinetti, A. Pietrangelo,  
15 E. Clini, M. Girardis, G. Guaraldi, C. Mussini, A. Cossarizza, Marked T cell activation,  
16 senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia,  
17 *Nature Communications* **11**, 1199–17 (2020).
- 18 33. M.-S. Rha, H. W. Jeong, J.-H. Ko, S. J. Choi, I.-H. Seo, J. S. Lee, M. Sa, A. R. Kim, E.-J.  
19 Joo, J. Y. Ahn, J. H. Kim, K.-H. Song, E. S. Kim, H. B. Kim, Y. K. Kim, S.-H. Park, J. Y. Choi,  
20 K. R. Peck, E.-C. Shin, IFN- $\gamma$  is Produced by Pd-1 + Cells Among SARS-CoV-2-Specific MHC-  
21 I Multimer+CD8 + T Cells in Acute and Convalescent COVID-19 Patients. Available at SSRN:  
22 <https://ssrn.com/abstract=3684758> (2020).
- 23 34. K. N. Couper, D. G. Blount, E. M. Riley, IL-10: the master regulator of immunity to  
24 infection, *J. Immunol.* **180**, 5771–5777 (2008).
- 25 35. J. Sun, R. Madan, C. L. Karp, T. J. Braciale, Effector T cells control lung inflammation  
26 during acute influenza virus infection by producing IL-10, *Nat Med* **15**, 277–284 (2009).
- 27 36. A. Grifoni, J. Sidney, Y. Zhang, R. H. Scheuermann, B. Peters, A. Sette, A Sequence  
28 Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses  
29 to SARS-CoV-2, *Cell Host and Microbe* **27**, 671–680.e2 (2020).

30

31

### 32 **Acknowledgements:**

33 We thank Xin Mei Ong, Wan Rong Sia, Madeline Kwek and Charles Tiu for performing the  
34 surrogate virus neutralization testing in this study.



1 **Funding:**

2 Special NUHS COVID-19 Seed Grant Call, Project NUHSRO/2020/052/RO5+5/NUHS-  
3 COVID/6; emergency COVID-19 funds from the Saw Swee Hock School of Public Health and  
4 the National University of Singapore; Singapore National Research Foundation (NRF2016NRF-  
5 NSFC002-013) and Singapore Ministry of Health's National Medical Research Council (STPRG-  
6 FY19-001, COVID19RF-003, COVID19RF3-0060).

7 **Author contributions:**

8 NLB, ATT and AB designed the experiments; HEC and LYH conceived and contributed to study  
9 design for the migrant workers study; WNC, BLL, LFW, SHL, WYW performed antibody analysis;  
10 CYLT, KK, JMEL and AC performed all other experiments and analyzed data; JML, LT, NS, MZ,  
11 ZMT, VK, LJS contributed to design and implementation of the migrant workers study; NLB,  
12 CAD and AB analyzed and interpreted the data and prepared the figures; NLB and AB wrote the  
13 paper; YJT, PAT, SK, DL, JGHL recruited COVID-19 patients and provided all clinical data. AB  
14 designed and coordinated the study; CCT conceived and led the migrant workers study.

15

16 **Figures:**

17 **Fig. 1. Enrolment of SARS-CoV-2 exposed donors.** (A) Confirmed cases of SARS-CoV-2  
18 infection in Singapore, divided into imported cases (red), cases among dormitory residents (blue)  
19 and all other community cases (yellow). The black arrows indicate the dates when blood samples  
20 were taken for the study. (B) Diagram showing the number of participants that were invited and  
21 recruited into the study. Participants who completed blood donations at recruitment and at 2- and  
22 6-weeks follow-up were tested for serology of anti-NP IgG (Abbott) and sVNT-nAb (GenScript).

1 An additional blood sample was taken at week 6 from 85 asymptomatic participants with distinct  
2 serological profiles for the analysis of SARS-CoV-2-specific T cell responses.

3 \*Symptoms: any of fever, cough, runny nose, sore throat, shortness of breath, fatigue, muscle ache,  
4 diarrhea or anosmia

5 **Fig. 2. SARS-CoV-2-specific antibody profile shows increasing infection prevalence among**  
6 **the dormitory residents during the study period. (A)** Percentage of donors positive for anti-NP  
7 IgG (black) and neutralizing antibodies (grey) at recruitment and after 2 and 6 weeks; antibody  
8 positive donors who experienced COVID-19 symptoms before (yellow) and during (red) the study  
9 are highlighted. **(B)** Dot plots show longitudinally the quantity of anti-NP IgG antibodies (y-axis)  
10 and the % inhibition by virus neutralization antibodies (sVNT; x-axis) in the serum of 434  
11 asymptomatic study participants at recruitment (left), after 2 weeks (middle) and after 6 weeks  
12 (right). The grey area marks the limit of assay detection. Spearman correlation. **(C)** Longitudinal  
13 anti-NP IgG levels of asymptomatic donors who were seropositive at recruitment (left; n=106,  
14 left), who seroconverted at week 2 (n=52, middle) and who seroconverted by week 6 (n=77, right).  
15 **(D)** Anti-NP IgG serological profile of donors selected for SARS-CoV-2-specific T cell analysis  
16 at the 6-week timepoint. Donors with distinct antibody profiles are shown in different colors and  
17 are summarized in the table.

18 **Fig. 3. Frequency of T cells specific for different SARS-CoV-2 proteins in asymptomatic**  
19 **donors with distinct serological profiles. (A)** SARS-CoV-2 proteome organization; analyzed  
20 proteins have a red outline and are marked by \*. 15-mer peptides overlapping by 10 amino acids  
21 were split into pools covering nucleoprotein (NP1, NP-2) and membrane (M) and selected 15-mers  
22 covering the more T cell immunogenic regions of Spike (S). T cell-reactivity was tested by ex vivo

1 IFN- $\gamma$ -ELISpot. **(B)** The frequency of IFN- $\gamma$ -spot forming cells (SFC) reactive to the individual  
2 peptide pools is shown for the asymptomatic donors with distinct serological profiles (line =  
3 median). IFN- $\gamma$ -SFC  $\geq 10/10^6$  PBMC were considered positive (grey area is below limit of  
4 detection). Circles below represent the percentage of a positive response (red) to the individual  
5 peptide pools.

6 **Fig. 4. Dynamics and hierarchy of SARS-CoV-2-specific T cells in asymptomatic and**  
7 **symptomatic infection.** **(A)** The frequency of IFN- $\gamma$ -spot forming cells (SFC) reactive to the  
8 individual peptide pools is shown for asymptomatic SARS-CoV-2-infected donors who were  
9 serologically positive for anti-NP-IgG on at least one timepoint during the study period (n=72;  
10 left), for COVID-19 patients from acute to 3 months post infection (n=45; middle) and archived  
11 unexposed controls (n=51; right) (Line = median). Circles below represent the frequency of a  
12 positive (IFN- $\gamma$ -SFC  $\geq 10/10^6$  PBMC) response (red) to the individual peptide pools. RM one-way  
13 ANOVA with Greenhouse-Geisser correction, followed by Holm-Sidak's multiple comparisons  
14 test. **(B)** Bar graphs show the percentage of donors reacting to the number of peptide pools tested.  
15 **(C)** Frequency of IFN- $\gamma$ -SFC reactive to the individual peptide pools is shown for each donor of  
16 the asymptomatic cohort (n=72). Donors are organized according to their serological status of anti-  
17 NP IgG antibodies. **(D)** The frequency of IFN- $\gamma$ -SFC reactive to the individual peptide pools is  
18 shown in asymptomatic donors grouped by anti-NP IgG status. **(E)** Frequency of IFN- $\gamma$ -SFC  
19 reactive to the individual peptide pools is shown for symptomatic COVID-19 patients organized  
20 by months post clearance of SARS-CoV-2 infection (n=82). **(F)** The frequency of IFN- $\gamma$ -SFC  
21 reactive to the individual peptide pools is shown in COVID-19 patients grouped by months post  
22 infection. **(G)** Frequency of SARS-CoV-2-peptide reactive cells in individuals with asymptomatic  
23 (blue) and symptomatic (red) infection during the acute phase till 1-month post recovery (left), in

1 convalescents 2-3 months post infection (middle) and in asymptomatic at 2-3 months and in  
2 symptomatic at 4-7 months post infection (right). Mann-Whitney test.

3 **Fig. 5. Cytokine secretion profile of whole blood from asymptomatic and symptomatic**  
4 **convalescents stimulated with SARS-CoV-2-peptide pools.** (A) Schematic of whole blood  
5 stimulation with SARS-CoV-2-peptide pools overnight and analysis of the cytokine secretion  
6 profile (after DMSO control subtraction) using unsupervised clustering algorithm UMAP. (B)  
7 UMAP plots with cytokine secretion heatmaps. (C) Concatenated cytokine secretion profiles of  
8 peptide-pool stimulated whole blood from asymptomatic SARS-CoV-2 infected (left, blue, 31  
9 donors, 121 tests), SARS-CoV-2 unexposed (middle, blue, 9 donors, 36 tests) and SARS-CoV-2  
10 infected with mild (right, orange, 31 donors, 96 tests) and moderate to severe symptoms (right, red,  
11 8 donors, 21 tests) overlaid on the global UMAP plot of all analyzed samples (black dots; each dot  
12 corresponds to one culture supernatant). (D) The cytokine secretion profile of the samples from  
13 the asymptomatic cohort separated by donors who seroconverted to anti-NP IgG+ < 4 weeks ago  
14 (left), who were persistently seropositive (middle) and those who lost anti-NP IgG during the 6-  
15 week study period (right). (E) The cytokine secretion profile of the samples from the symptomatic  
16 cohort separated by donors who are in the 1st months (left), 2<sup>nd</sup> months (middle) and 3<sup>rd</sup> - 5<sup>th</sup>  
17 months (right) post SARS-CoV-2 infection. (F) The amount of indicated cytokines secreted upon  
18 whole blood stimulation with the peptide pools is compared between donors who had recently (<4  
19 weeks ago) an asymptomatic (blue) or a symptomatic (red) SARS-CoV-2 infection. Line = median  
20 concentration. Kruskal Wallis (non-parametric one-way ANOVA) followed by Dunn's multiple  
21 comparisons test.

22 **Fig. 6. Frequency and function of SARS-CoV-2-peptide pool reactive cells.** (A) The frequency  
23 of IFN- $\gamma$ -spot-forming cells (SFC) reactive to the peptide pools analyzed by ELISpot assay (x-axis)

1 is plotted against the amount of the cytokines secreted following whole blood stimulation with the  
2 identical peptide pools (y-axis) of the asymptomatic cohort. Samples from donors with the recent  
3 SARS-CoV-2 infection (<4 weeks anti-NP IgG+) are highlighted in blue. Spearman correlation.  
4 **(B)** The frequency of IFN- $\gamma$ -secreting cells (SFC) reactive to the peptide pools analyzed by  
5 ELISpot assay (x-axis) is plotted against the amount of the cytokines secreted following whole  
6 blood stimulation with the identical peptide pools (y-axis) of the symptomatic cohort. Samples  
7 from donors with the recent SARS-CoV-2 infection (<4 weeks PCR neg) are highlighted in red.  
8 Spearman correlation.

9

#### 10 **Supplementary Materials:**

11 **Fig. S1. Kinetics of SARS-CoV-2 neutralizing antibody profile in the asymptomatic study**  
12 **cohort.** Longitudinal levels of neutralizing antibodies measured as % inhibition by surrogate virus  
13 neutralization test (sVNT) in asymptomatic donors who were seropositive at recruitment (left;  
14 n=134, left), who seroconverted at week 2 (n=81, middle) and who seroconverted by week 6 (n=93,  
15 right). The grey area marks the limit of assay detection.

16 **Fig. S2. T cells reactive to different pools of Spike peptides in COVID-19 convalescents.** Spike  
17 is a long protein with 1276 amino acids, thus it requires 253 15-mer peptides overlapping by 10  
18 amino acids to cover the whole protein, thus 7 pools of about 40 peptides. To reduce the number  
19 of peptides pools to test, we selected a single “Spike pool” comprised of 55 peptides. For the  
20 selection, all sequences of published SARS-CoV-1 epitopes ([www.iedb.org](http://www.iedb.org); positive assays only,  
21 T cells assays, host: human) were aligned with the library of Spike-SARS-CoV-2 15-mers. We  
22 selected the 15-mer peptides that cover the homologue sequence of the described SARS-CoV-1


1 epitope sequences. In addition, we added the 15-mer peptides that cover the predicted SARS-CoV-  
2 Spike epitopes published by Grifoni et al (36). The 55 peptides cover 40.5% of the Spike protein.  
3 The frequency of reactive cells to the selected Spike pool (red) was compared to the 7 pools of 15-  
4 mers overlapping by 10 amino acids covering together the entire Spike protein (S1-S7) in 15  
5 COVID-19 convalescents.

6 **Fig. S3. CD4+ and CD8+ T cells are reactive to stimulation with SARS-CoV-2-specific**  
7 **peptides.** For 3 asymptomatic donors (<4 weeks anti-NP IgG+), short-term T cell lines were  
8 generated by PBMC stimulation with the different peptide pools and a 10-day expansion protocol  
9 (19). A peptide pool-matrix strategy was applied which identified single T cell epitopes.  
10 Subsequently, the short-term T cell lines were re-stimulated for 5h with the identified single  
11 peptides and analyzed by intracellular cytokine staining for IFN- $\gamma$ . (A) The gating strategy to  
12 identify CD4+ and CD8+ T cells is shown. (B) Dot plots show examples of CD4+ and CD8+ T  
13 cells producing IFN- $\gamma$  in response to stimulation with three different peptides (upper panels) and  
14 the corresponding unstimulated controls (lower panels).

15 **Fig. S4. Cytokines produced by immune cells following stimulation with SARS-CoV-2**  
16 **peptide pools.** PBMC were stimulated for 5h (or 7h for IL-6) with SARS-CoV-2 peptide pools  
17 and analyzed by intracellular cytokine staining. (A) The gating strategy to identify the different  
18 immune cell subsets is shown. (B) Dot plots show examples of T cells producing IFN- $\gamma$ , TNF- $\alpha$ ,  
19 IL-2 and monocytes producing IL-6 in response to stimulation with the M peptide pool (red)  
20 overlaid with the corresponding unstimulated controls (black).

21 **Table S1: Cohort of symptomatic COVID-19 patients.** SARS-CoV-2-specific T cells for S, M,  
22 NP-1 and NP-2 were analyzed in 76 COVID-19 patients by ELISpot assay. From 16 patients, T

- 1 cells were tested longitudinally at 2-3 different timepoints post PCR negativity. In addition, whole
- 2 blood was stimulated with the peptide pools from 38 donors, 1 donor was tested on two different
- 3 time points. The tested samples are labelled with +.




**Fig. 1. Enrolment of SARS-CoV-2 exposed donors.**

**(A)** Confirmed cases of SARS-CoV-2 infection in Singapore, divided into imported cases (red), cases among dormitory residents (blue) and all other community cases (yellow). The black arrows indicate the dates when blood samples were taken for the study. **(B)** Diagram showing the number of participants that were invited and recruited into the study. Participants who completed blood donations at recruitment and at 2- and 6-weeks follow-up were tested for serology of anti-NP IgG (Abbott) and sVNT-nAb (GenScript). An additional blood sample was taken at week 6 from 85 asymptomatic participants with distinct serological profiles for the analysis of SARS-CoV-2-specific T cell responses.


\*Symptoms: any of fever, cough, runny nose, sore throat, shortness of breath, fatigue, muscle ache, diarrhea or anosmia






**Fig. 2. SARS-CoV-2-specific antibody profile shows increasing infection prevalence among the dormitory residents during the study period.**

(A) Percentage of donors positive for anti-NP IgG (black) and neutralizing antibodies (grey) at recruitment and after 2 and 6 weeks; antibody positive donors who experienced COVID-19 symptoms before (yellow) and during (red) the study are highlighted. (B) Dot plots show longitudinally the quantity of anti-NP IgG antibodies (y-axis) and the % inhibition by virus neutralization antibodies (sVNT; x-axis) in the serum of 434 asymptomatic study participants at recruitment (left), after 2 weeks (middle) and after 6 weeks (right). The grey area marks the limit of assay detection. Spearman correlation. (C) Longitudinal anti-NP IgG levels of asymptomatic donors who were seropositive at recruitment (left; n=106, left), who seroconverted at week 2 (n=52, middle) and who seroconverted by week 6 (n=77, right). (D) Anti-NP IgG serological profile of donors selected for SARS-CoV-2-specific T cell analysis at the 6-week timepoint. Donors with distinct antibody profiles are shown in different colors and are summarized in the table.




**Fig. 3. Frequency of T cells specific for different SARS-CoV-2 proteins in asymptomatic donors with distinct serological profiles.**

(A) SARS-CoV-2 proteome organization; analyzed proteins have a red outline and are marked by \*. 15-mer peptides overlapping by 10 amino acids were split into pools covering nucleoprotein (NP1, NP-2) and membrane (M) and selected 15-mers covering the more T cell immunogenic regions of Spike (S). T cell-reactivity was tested by ex vivo IFN- $\gamma$ -ELISpot. (B) The frequency of IFN- $\gamma$ -spot forming cells (SFC) reactive to the individual peptide pools is shown for the asymptomatic donors with distinct serological profiles (line = median). IFN- $\gamma$ -SFC  $\geq 10/10^6$  PBMC were considered positive (grey area is below limit of detection). Circles below represent the percentage of a positive response (red) to the individual peptide pools.



**Fig. 4. Dynamics and hierarchy of SARS-CoV-2-specific T cells in asymptomatic and symptomatic infection.**


(A) The frequency of IFN- $\gamma$ -spot forming cells (SFC) reactive to the individual peptide pools is shown for asymptomatic SARS-CoV-2-infected donors who were serologically positive for anti-NP-IgG on at least one timepoint during the study period (n=72; left), for COVID-19 patients from acute to 3 months post infection (n=45; middle) and archived unexposed controls (n=51; right) (Line = median). Circles below represent the frequency of a positive (IFN- $\gamma$ -SFC  $\geq 10/10^6$  PBMC) response (red) to the individual peptide pools. RM one-way ANOVA with Greenhouse-Geisser correction, followed by Holm-Sidak's multiple comparisons test. (B) Bar graphs show the percentage of donors reacting to the number of peptide pools tested. (C) Frequency of IFN- $\gamma$ -SFC reactive to the individual peptide pools is shown for each donor of the asymptomatic cohort (n=72). Donors are organized according to their serological status of anti-NP IgG antibodies. (D) The frequency of IFN- $\gamma$ -SFC reactive to the individual peptide pools is shown in asymptomatic donors grouped by anti-NP IgG status. (E) Frequency of IFN- $\gamma$ -SFC reactive to the individual peptide pools is shown for symptomatic COVID-19 patients organized by months post clearance of SARS-CoV-2 infection (n=82). (F) The frequency of IFN- $\gamma$ -SFC reactive to the individual peptide pools is shown in COVID-19 patients grouped by months post infection. (G) Frequency of SARS-CoV-2-peptide reactive cells in individuals with asymptomatic (blue) and symptomatic (red) infection during the acute phase till 1-month post recovery (left), in convalescents 2-3 months post infection (middle) and in asymptomatic at 2-3 months and in symptomatic at 4-7 months post infection (right). Mann-Whitney test.




**Fig. 5. Cytokine secretion profile of whole blood from asymptomatic and symptomatic convalescents stimulated with SARS-CoV-2-peptide pools.**

(A) Schematic of whole blood stimulation with SARS-CoV-2-peptide pools overnight and analysis of the cytokine secretion profile (after DMSO control subtraction) using unsupervised clustering algorithm UMAP. (B) UMAP plots with cytokine secretion heatmaps. (C) Concatenated cytokine secretion profiles of peptide-pool stimulated whole blood from asymptomatic SARS-CoV-2 infected (left, blue, 31 donors, 121 tests), SARS-CoV-2 unexposed (middle, grey, 9 donors, 36 tests) and SARS-CoV-2 infected with mild (right, orange, 31 donors, 96 tests) and moderate to severe symptoms (right, red, 8 donors, 21 tests) overlaid on the global UMAP plot of all analyzed samples (black dots; each dot corresponds to one culture supernatant). (D) The cytokine secretion profile of the samples from the asymptomatic cohort separated by donors who seroconverted to anti-NP IgG+ < 4 weeks ago (left), who were persistently seropositive (middle) and those who lost anti-NP IgG during the 6-week study period (right). (E) The cytokine secretion profile of the samples from the symptomatic cohort separated by donors who are in the 1<sup>st</sup> months (left), 2<sup>nd</sup> months (middle) and 3<sup>rd</sup> - 5<sup>th</sup> months (right) post SARS-CoV-2 infection. (F) The amount of indicated cytokines secreted upon whole blood stimulation with the peptide pools is compared between donors who had recently (< 4 weeks ago) an asymptomatic (blue) or a symptomatic (red) SARS-CoV-2 infection. Line = median concentration. Kruskal Wallis (non-parametric one-way ANOVA) followed by Dunn's multiple comparisons test.

**A**




**B**




**Fig. 6. Frequency and function of SARS-CoV-2-peptide pool reactive cells.**

(A) The frequency of IFN- $\gamma$ -spot-forming cells (SFC) reactive to the peptide pools analyzed by ELISpot assay (x-axis) is plotted against the amount of the cytokines secreted following whole blood stimulation with the identical peptide pools (y-axis) of the asymptomatic cohort. Samples from donors with the recent SARS-CoV-2 infection (<4 weeks anti-NP IgG+) are highlighted in blue. Spearman correlation. (B) The frequency of IFN- $\gamma$ -secreting cells (SFC) reactive to the peptide pools analyzed by ELISpot assay (x-axis) is plotted against the amount of the cytokines secreted following whole blood stimulation with the identical peptide pools (y-axis) of the symptomatic cohort. Samples from donors with the recent SARS-CoV-2 infection (<4 weeks PCR neg) are highlighted in red. Spearman correlation.




**Fig. S1. Kinetics of SARS-CoV-2 neutralizing antibody profile in the asymptomatic study cohort.**

Longitudinal levels of neutralizing antibodies measured as % inhibition by surrogate virus neutralization test (sVNT) in asymptomatic donors who were seropositive at recruitment (left; n=134, left), who seroconverted at week 2 (n=81, middle) and who seroconverted by week 6 (n=93, right). The grey area marks the limit of assay detection.



**Fig. S2. T cells reactive to different pools of Spike peptides in COVID-19 convalescents.**

Spike is a long protein with 1276 amino acids, thus it requires 253 15-mer peptides overlapping by 10 amino acids to cover the whole protein, thus 7 pools of about 40 peptides. To reduce the number of peptides pools to test, we selected a single “Spike pool” comprised of 55 peptides. For the selection, all sequences of published SARS-CoV-1 epitopes ([www.iedb.org](http://www.iedb.org); positive assays only, T cells assays, host: human) were aligned with the library of Spike-SARS-CoV-2 15-mers. We selected the 15-mer peptides that cover the homologue sequence of the described SARS-CoV-1 epitope sequences. In addition, we added the 15-mer peptides that cover the predicted SARS-CoV-2 Spike epitopes published by Grifoni et al (36). The 55 peptides cover 40.5% of the Spike protein. The frequency of reactive cells to the selected Spike pool (red) was compared to the 7 pools of 15-mers overlapping by 10 amino acids covering together the entire Spike protein (S1-S7) in 15 COVID-19 convalescents.




**Fig. S3. CD4+ and CD8+ T cells are reactive to stimulation with SARS-CoV-2-specific peptides.**


For 3 asymptomatic donors (<4 weeks anti-NP IgG+), short-term T cell lines were generated by PBMC stimulation with the different peptide pools and a 10-day expansion protocol (19). A peptide pool-matrix strategy was applied which identified single T cell epitopes. Subsequently, the short-term T cell lines were re-stimulated for 5h with the identified single peptides and analyzed by intracellular cytokine staining for IFN- $\gamma$ . **(A)** The gating strategy to identify CD4+ and CD8+ T cells is shown. **(B)** Dot plots show examples of CD4+ and CD8+ T cells producing IFN- $\gamma$  in response to stimulation with three different peptides (upper panels) and the corresponding unstimulated controls (lower panels).



**A**



**B**



**Fig. S4. Cytokines produced by immune cells following stimulation with SARS-CoV-2 peptide pools.**

PBMC were stimulated for 5h (or 7h for IL-6) with SARS-CoV-2 peptide pools and analyzed by intracellular cytokine staining. **(A)** The gating strategy to identify the different immune cell subsets is shown. **(B)** Dot plots show examples of T cells producing IFN- $\gamma$ , TNF- $\alpha$ , IL-2 and monocytes producing IL-6 in response to stimulation with the M peptide pool (red) overlaid with the corresponding unstimulated controls (black).

**Table S1: Cohort of symptomatic COVID-19 patients**

SARS-CoV-2-specific T cells for S, M, NP-1 and NP-2 were analyzed in 76 COVID-19 patients by ELISpot assay. From 16 patients, T cells were tested longitudinally at 2-3 different timepoints post PCR negativity. In addition, whole blood was stimulated with the peptide pools from 38 donors, 1 donor was tested on two different time points. The tested samples are labelled with +.

COVID-19 patient ID	Age	Gender	Residence	Ethnicity	*Disease severity	Symptom onset to PCR negativity (days)	Samples tested by ELISpot (and whole blood +) in days post PCR negativity	
#002	44	F	Singapore	Indonesia	mild	n/a	acute	
#121	64	M	Singapore	Chinese	severe	27	acute	8 133 (+)
#063	44	F	Singapore	Chinese	mild	13	acute	142 (+)
#005	70	M	Singapore	Chinese	severe +	n/a	acute	
#065	65	F	Singapore	Chinese	mild	22	acute	1 106 (+)
#069	32	M	Singapore	Caucasian	mild	25	acute	22 99 (+)
#070	32	F	Singapore	Chinese	mild	29	acute	91 (+)
#071	65	M	Singapore	Chinese	severe	19	acute	12
#072	78	M	Singapore	Caucasian	mild	29	acute	104 (+)
#076	27	F	Singapore	Indian	mild	16	acute	37
#077	58	M	Singapore	Chinese	moderate	n/a	acute	
#086	32	F	Singapore	Chinese	mild	13	acute	95 (+)
#120	70	M	Singapore	Indian	severe	83	1 (+)	10
#127	42	M	Singapore	Indian	mild	18	1 (+)	49 (+)
#138	69	F	Singapore	Chinese	severe	23	1 (+)	
#139	66	M	Singapore	Indian	severe	39	1 (+)	
#156	50	M	Singapore	Chinese	mild	19	2	39
#003	35	M	Singapore	Indian	mild	21	2	
#170	27	M	Singapore	Indian	mild	29	3 (+)	
#172	30	M	Singapore	Indian	mild	45	3 (+)	
#174	51	M	Singapore	Chinese	mild	44	3 (+)	
#176	42	M	Singapore	Bangaldeshi	mild	52	3 (+)	
#104	61	F	Singapore	Japanese	severe	31	4 (+)	
#078	34	M	Singapore	Chinese	mild	31	11 (+)	
#133	55	M	Singapore	Chinese	severe	22	15	67
#098	29	F	Singapore	Chinese	mild	11	17 (+)	
#085	37	M	Singapore	Caucasian	mild	50	19 (+)	
#091	53	M	Singapore	Caucasian	mild	34	19 (+)	
#069	32	M	Singapore	Caucasian	mild	25	22 (+)	
#081	35	F	Singapore	Caucasian	mild	25	23 (+)	
#164	50	M	Singapore	Bangaldeshi	mild	15	23 (+)	
#097	39	M	Singapore	Chinese	mild	38	26 (+)	
#075	39	M	Singapore	Caucasian	mild	23	26 (+)	
#166	48	M	Singapore	Chinese	mild	15	28	
#095	25	F	Singapore	Chinese	mild	54	32	
#110	40	M	Singapore	Indian	moderate	38	32 (+)	
#082	25	M	Singapore	Chinese	mild	19	34	118 (+)
#P22	55	M	Singapore	Malay	mild	10	34	
#122	65	M	Singapore	Chinese	mild	30	38 (+)	
#P19	64	M	Singapore	Indian	mild	12	38	
#154	49	M	Singapore	Indian	mild	16	43 (+)	
#109	48	M	Singapore	Chinese	mild	14	45 (+)	
#158	24	M	Singapore	Indian	mild	19	45 (+)	
#093	40	F	Singapore	Hispanic	mild	41	47 (+)	
#160	50	M	Singapore	Indian	mild	15	49 (+)	
#153	32	M	Singapore	Indian	mild	14	50	
#P13	38	F	Singapore	Malay	mild	17	56 (+)	
#159	22	F	Singapore	Indian	mild	35	65	
#133	64	M	Singapore	Chinese	severe	22	67 (+)	
#P06	43	M	Singapore	Indian	mild	17	90	174
#P04	39	F	Singapore	Chinese	mild	4	107	189
#C-T095	64	M	Singapore	Chinese	mild	unknown	167	
#C-T087	53	F	Singapore	Chinese	mild	unknown	168	
#C-T186	45	M	Singapore	Chinese	severe	unknown	168	
#C-T040	25	M	Singapore	Chinese	mild	unknown	169	
#C-T032	52	M	Singapore	Chinese	severe	unknown	170	
#C-T073	65	F	Singapore	Chinese	mild	unknown	175	
#C-T153	52	M	Singapore	?	moderate	unknown	175	
#C-T035	57	F	Singapore	Chinese	mild	unknown	177	
#C-T157	59	M	Singapore	Chinese	mild	unknown	177	
#C-T038	27	F	Singapore	Chinese	mild	unknown	179	
#C-T041	61	M	Singapore	Chinese	mild	unknown	179	
#C-T098	62	M	Singapore	Chinese	mild	unknown	179	
#C-T154	72	M	Singapore	Chinese	severe	unknown	179	
#C-T018	52	F	Singapore	Chinese	mild	unknown	180	
#C-T029	51	F	Singapore	Chinese	mild	unknown	180	
#C-T052	30	F	Singapore	Chinese	mild	unknown	180	
#C-C003	36	F	Singapore	?	mild	unknown	181	
#C-T016	27	M	Singapore	Chinese	mild	unknown	181	
#C-T028	26	M	Singapore	Chinese	mild	unknown	181	
#C-T101	61	F	Singapore	Chinese	mild	unknown	181	
#C-T145	32	M	Singapore	Chinese	mild	unknown	182	
#C-T163	67	F	Singapore	Chinese	mild	unknown	182	
#C-T165	62	F	Singapore	Chinese	mild	unknown	183	
#C-T133	44	M	Singapore	?	mild	unknown	184	
#C-T118	38	F	Singapore	Chinese	mild	unknown	193	

\* Definition of disease severity:

Mild: with or without CXR changes; not requiring oxygen supplement

Moderate: oxygen supplement less than 50%

Severe: oxygen supplement 50% or more or high flow oxygen or intubation